European Urology Oncology

Slides:

Advertisements

Similar presentations

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy,

Advertisements

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly Brent K. Hollenbeck, Samuel R. Kaufman, Phyllis.

Volume 4, Issue 5, Pages (September 2017)

Volume 61, Issue 6, Pages (June 2012)

Volume 69, Issue 5, Pages (May 2016)

Volume 70, Issue 1, Pages (July 2016)

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

Volume 60, Issue 5, Pages (November 2011)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 53, Issue 5, Pages (May 2008)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

European Urology Oncology

European Urology Oncology

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 71, Issue 5, Pages (May 2017)

European Urology Oncology

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 73, Issue 2, Pages (February 2018)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Global Burden of Urologic Cancers, 1990–2013

Volume 61, Issue 6, Pages (June 2012)

Volume 71, Issue 1, Pages (January 2017)

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer Valeria.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

European Urology Oncology

Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial Eva Johansson,

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Volume 55, Issue 3, Pages (March 2009)

European Urology Oncology

Volume 72, Issue 4, Pages (October 2017)

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

European Urology Oncology

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

European Urology Oncology

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

European Urology Oncology

Volume 68, Issue 1, Pages (July 2015)

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

The Cost to Medicare of Bladder Cancer Care

European Urology Oncology

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

European Urology Oncology

European Urology Oncology

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

European Urology Oncology Trends in Conservative Management for Low-risk Prostate Cancer in a Population- based Cohort of Australian Men Diagnosed Between 2009 and 2016 Wee Loon Ong, Sue M. Evans, Melanie Evans, Mark Tacey, Lachlan Dodds, Paul Kearns, Roger L. Milne, Farshad Foroudi, Jeremy Millar European Urology Oncology DOI: 10.1016/j.euo.2019.04.006 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 Management of low-risk prostate cancer (LRPC) in Victoria from 2009 to 2016, stratified by age groups. WW=watchful waiting; AS=active surveillance; RP=radical prostatectomy; EBRT=external beam radiotherapy; BT=brachytherapy; ADT=androgen deprivation therapy. European Urology Oncology DOI: (10.1016/j.euo.2019.04.006) Copyright © 2019 European Association of Urology Terms and Conditions